Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Jordan Chussler

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months. 

In large part, that rebound was fueled by increasing demand for weight-loss drugs such as GLP-1 agonists and semaglutide treatments, including Ozempic, Wegovy, Zepbound, and Mounjaro. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.